GLP-1 Side Effects: What the Big Trials Actually Report

Most talk about GLP-1 side effects runs on anecdote. The large randomized trials of semaglutide and tirzepatide measured these effects directly, against placebo, in thousands of people. This guide sticks to what those trials and the meta-analyses that pool them actually report. Every number below comes from a published abstract.

Two terms first. A GLP-1 receptor agonist mimics a gut hormone involved in appetite and blood-sugar control. Tirzepatide also acts on a second gut-hormone receptor, GIP. For the efficacy side of the comparison, see semaglutide vs tirzepatide.

Gastrointestinal effects, and why titration exists

Stomach and bowel symptoms are the most common side effects, and it isn't close.

In STEP 1, 1,961 adults without diabetes received 2.4 mg of semaglutide weekly or placebo for 68 weeks. Nausea and diarrhea were the most common adverse events. They were "typically transient and mild-to-moderate" and eased over time. Still, 4.5% of the semaglutide group stopped treatment because of GI events, compared with 0.8% on placebo (Wilding 2021).

A pooled analysis of STEP 1-3 gives the specific rates, semaglutide vs placebo (Wharton 2022):

The same analysis found that 99.5% of these events were non-serious and 98.1% were mild to moderate. They happened most often during or shortly after dose escalation. It also answered a common question: does the nausea cause the weight loss? Apparently not. Less than one percentage point of the extra weight loss was explained by GI events.

Tirzepatide shows the same pattern. In SURMOUNT-1 (2,539 adults, 72 weeks), GI events were the most common adverse events. Most were mild to moderate and happened "primarily during dose escalation." Adverse events led to stopping treatment in 4.3%, 7.1% and 6.2% of the 5, 10 and 15 mg groups, compared with 2.6% on placebo (Jastreboff 2022).

That timing is why these trials start low and step up gradually, a process called titration. STEP 1 built 16 weeks of dose escalation into its schedule before participants reached 2.4 mg (Wilding 2022). SURMOUNT-1 used a 20-week escalation period. These are the trials' own schedules, reported here to explain the design. They are not recommendations.

Gallbladder and biliary disease

The gallbladder signal is the most consistent one in the pooled data. A meta-analysis of 76 randomized trials with 103,371 patients found that GLP-1 drugs were linked to a higher risk of gallbladder or biliary disease overall (relative risk 1.37). Specific risks were raised for gallstones (1.27) and gallbladder inflammation, or cholecystitis (1.36) (He 2022).

A relative risk compares rates between groups. It isn't the chance of any one person getting the condition. The same analysis found the risk was higher:

• in weight-loss trials (relative risk 2.29) than in diabetes and other trials (1.27)
• at higher doses (1.56) than at lower doses (0.99)
• with longer use (1.40) than with shorter use (0.79)

An earlier meta-analysis of 113 trials in type 2 diabetes also found more gallstones with GLP-1 drugs (odds ratio 1.30) (Monami 2017).

The pancreatitis question

Pancreatitis is inflammation of the pancreas. It is the side effect people ask about most, and the evidence is more mixed than either side usually admits.

GLP-1 drug labels warn about acute pancreatitis (Storgaard 2017). The pooled trial data, though, have not shown a clear increase:

• Three long-term trials in type 2 diabetes, where independent committees adjudicated pancreatitis cases, found no increased risk (Peto odds ratio 0.745, 95% CI 0.47-1.17). The authors added that more evidence is needed (Storgaard 2017).
• Across 113 diabetes trials, pancreatitis rates did not differ significantly from comparators (odds ratio 0.93) (Monami 2017).
• A 2026 meta-analysis of 52 studies in people using these drugs for weight management found no significant association (odds ratio 1.29, 95% CI 0.91-1.84) (Zhong 2026).
• For tirzepatide, 19 trials with 15,471 participants found acute pancreatitis in 0.22% and no dose-response between 5 and 15 mg. The authors noted that precision "remains limited" and that all the trials were industry-funded with short-to-moderate follow-up (Benny 2026).

Put fairly: pooled trials have not confirmed a signal, but pancreatitis is rare, and trials of this size and length can miss rare events. "Not shown to increase risk" is not the same as "shown to be safe."

Lean mass loss

When people lose weight by any method, some of the loss is lean mass, not fat. The question is how much.

In a SURMOUNT-1 substudy, 160 participants had DXA body-composition scans. On tirzepatide, body weight fell 21.3%, fat mass fell 33.9% and lean mass fell 10.9%. About 75% of the weight lost was fat and about 25% was lean mass. That ratio was the same on placebo, where participants lost much less weight overall (Look 2025).

A 2026 meta-analysis of seven trials (821 patients) found the same two-sided picture. Absolute lean mass went down (-1.74 kg on average; -5.44 kg with semaglutide). But lean mass as a share of total body weight went up by 1.81%, because fat fell faster. The authors stressed pairing drug treatment with nutrition and exercise to protect muscle (Laverde 2026).

What these abstracts don't tell us is whether the lean mass lost affects strength or function over the long term. That question remains open.

Weight regain after stopping

This is the most consistent finding of all. The trials were built to test it directly.

STEP 1 extension. 327 participants were followed for one year after stopping semaglutide and the lifestyle program. They had lost 17.3% of body weight on treatment. By week 120 they had regained 11.6 percentage points, leaving a net loss of 5.6%, or about two-thirds of the lost weight regained. Most cardiometabolic improvements also moved back toward baseline (Wilding 2022).

STEP 4. After a 20-week run-in on semaglutide (average loss 10.6%), participants were randomized to continue or switch to placebo. Over the next 48 weeks, weight changed by -7.9% with continued semaglutide and +6.9% after switching to placebo (Rubino 2021).

SURMOUNT-4. After 36 weeks of open-label tirzepatide (average loss 20.9%), 670 participants were randomized. Over 52 weeks, weight changed by -5.5% with continued tirzepatide and +14.0% on placebo. Of those who stayed on tirzepatide, 89.5% kept at least 80% of their earlier loss, compared with 16.6% on placebo (Aronne 2024).

The STEP 1 extension authors concluded that the findings "confirm the chronicity of obesity." In these trials, the drugs worked while people took them, and most of the effect faded after they stopped.

Reading these numbers well

• These are averages from randomized controlled trials in carefully selected, monitored participants taking pharmaceutical-grade drug on a fixed titration schedule. Results elsewhere may differ.
• Most GI data come from the escalation phase. Both families of trials describe these events as mostly mild and short-lived.
• Relative risks describe differences between groups. Your own clinician is the right person to put them in context.

Each drug page on PeptideChat lists its research status and PubMed-verified studies. Our methodology explains how we check citations.

Sources

• Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2021. PMID 33567185
• Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab, 2022. PMID 34514682
• Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, 2022. PMID 35658024
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med, 2022. PMID 35344001
• Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab, 2017. PMID 28105738
• Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab, 2017. PMID 28244632
• Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis. Horm Metab Res, 2026. PMID 42600634
• Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials. Pancreatology, 2026. PMID 41927408
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab, 2025. PMID 39996356
• Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). Int J Obes (Lond), 2026. PMID 42321502
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab, 2022. PMID 35441470
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. PMID 33755728
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024. PMID 38078870

This article is for educational and research purposes only and is not medical advice.